23 Results for "

neoplastic cells

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "neoplastic cells" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-N6961
CAS No.: 84-79-7
Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99151
CAS No.: 2088770-90-3
Synonyms: CAC-10

Research Areas:  

Cancer

Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13072
CAS No.: 871357-89-0
Purity:  99.86%
Synonyms: AS-703569; R-763
Research Areas:  

Cancer

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
loading...
    loading...
Cat. No.: HY-N7844
CAS No.: 4294-16-0
Synonyms: Benzyladenosine
N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma - .
loading...
    loading...
Cat. No.: HY-43521
CAS No.: 1710768-30-1
Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .
loading...
    loading...
Cat. No.: HY-P3182
CAS No.: 9032-21-7
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

NADH oxidase is a cyanide-resistant oxidase located on the plasma membrane of animals and plants, which is regulated by growth factors and hormones. NADH oxidase catalyzes the electron transfer from NADH to oxygen, and its activity is closely related to cell growth. The hormone response of NADH oxidase is attenuated in tumor-transformed cells, and it can serve as an anti-tumor target .
loading...
    loading...
Cat. No.: HY-W587738
CAS No.: 552-02-3
Viridiflorol is an active natural molecule with anti-cancer effect. Viridiflorol induces anti-neoplastic effects on breast (MCF-7, IC50 = 10 µM), lung (A549, IC50 = 30 µM), and brain (Daoy, IC50 = 0.1 µM) cancer cells through apoptosis. Viridiflorol can be used for breast, lung, and brain cancer research .
loading...
    loading...
Cat. No.: HY-N3913
CAS No.: 911004-72-3
Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .
loading...
    loading...
Cat. No.: HY-13072R
CAS No.: 871357-89-0
Synonyms: AS-703569 (Standard); R-763 (Standard)
Research Areas:  

Cancer

Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
loading...
    loading...
Cat. No.: HY-W011788
CAS No.: 76-84-6
Synonyms: Trt-OH
Research Areas:  

Cancer

Triphenylmethanol is a specific clathrate host for methanol and dimethyl sulphoxide. Triphenylmethanol inhibits neoplastic transformation of cells .
loading...
    loading...
Cat. No.: HY-N6961R
CAS No.: 84-79-7
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
loading...
    loading...
Cat. No.: HY-129767
CAS No.: 2368900-35-8
Research Areas:  

Cancer

CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .
loading...
    loading...
Cat. No.: HY-144438
Research Areas:  

Cancer

Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of aurora and lim kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion. Aurora/LIM kinase-IN-1 is a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future agent development efforts for GBM, and potentially other cancers .
loading...
    loading...
Cat. No.: HY-W011788R
CAS No.: 76-84-6
Synonyms: Trt-OH (Standard)
Research Areas:  

Cancer

loading...
    loading...
Cat. No.: HY-120290
CAS No.: 168334-34-7
Purity:  99.30%
Research Areas:  

Cancer

PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
loading...
    loading...
Cat. No.: HY-13072B
CAS No.: 1145859-64-8
Synonyms: AS-703569 benzoate; R-763 benzoate
Research Areas:  

Cancer

Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
loading...
    loading...
Cat. No.: HY-P992366

Target:  

Galectin Tim3

Research Areas:  

Cancer

HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 + T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .
loading...
    loading...
Cat. No.: HY-182375A
CAS No.: 2764877-95-2
Target:  

LPL Receptor

Research Areas:  

Inflammation/Immunology Cancer

SLB1122168 free base is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 free base inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC50 of 94 nM. SLB1122168 free base induces lymphopenia in circulating lymphocytes in mice and rats .
loading...
    loading...
Cat. No.: HY-173172
CAS No.: 3076503-34-6
Research Areas:  

Cancer

MG-002 is an orally active eIF4A1 and eIF4A2 inhibitor with a human eIF4A1 IC50 of 43 nM. MG-002 prevents competent ribosome recruitment to mRNA, inhibits cap-dependent mRNA translation, and engages eIF4A2 via the same RNA clamping mechanism to inhibit mRNA translation. MG-002 induces G2/M cell cycle delay, induces apoptosis, suppresses synthesis of c-MYC and cyclin D1, and shows minimal overt toxicity in mice. MG-002 inhibits primary triple-negative breast cancer tumor growth, attenuates metastatic spread, and enhances anti-neoplastic activity of Doxorubicin (HY-15142A) in pre-clinical models .
loading...
    loading...
Cat. No.: HY-182375
CAS No.: 2764877-97-4
Target:  

LPL Receptor

Research Areas:  

Inflammation/Immunology

(R)-SLB1122168 free base, an isomer of SLB1122168 free base (HY-182375A), is a spinster homolog 2 (SPNS2) inhibitor with an IC50 ≤2 μM .
loading...
    loading...